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The recent outbreak in severe acute respiratory syndrome – coronavirus-2 (SARS-CoV-2)
has demonstrated the complete inability of nations across the world to cope with
the pressures of a global pandemic, especially one in which the only current feasible
treatments are those which deal with the symptoms alone and not the viral cause. As
the death toll rises, scientists begin to fall toward new avenues of research, with novelty
showing itself to be an incredible and so far, underrated resource. In this case, the use of
biosurfactants in dealing with this pandemic justifies extensive study with their potential
applications being in the prevention of viral spread; dealing with the symptoms that
develop after the incubation period; directly targeting viral infected cells and preventing
the spread of the virus throughout the host, all in addition to also acting as potential drug
delivery systems and cleaning agents. This extensive avenue of biosurfactants owes
to the simplicity in their amphiphilic structure which permits them to interact directly
with the lipid membrane of the coronavirus, in a way which wouldn’t be of significant
threat to the host. Although it could possibly interact and affect the virus, it could also
affect human internal organs/cells by interacting with lipid membrane, if (biosurfactant
is) ingested, and it still needs further studies in human models. The structure of the
coronavirus, in this case SARS-CoV-2, is detrimentally dependent on the integrity of
its lipid membrane which encloses its vital proteins and RNA. Biosurfactants possess
the innate ability to threaten this membrane, a result of their own hydrophobic domains
across their amphiphilic structure. With biosurfactants additionally being both natural and
sustainable, while also possessing a remarkably low cytotoxicity, it is of no doubt that they
are going to be of increasing significance in dealing with the current pandemic.
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INTRODUCTION
SARS-COV-2 poses a serious and escalating threat to public health, after having triggered a
pandemic that stems from its first recorded infection in Wuhan, China during early December
2019 (Hong et al., 2020). In many cases, infection will induce flu-like symptoms in the host who will
additionally become highly contagious, having an averaged R0 of roughly 3.28, even throughout the
initial incubation period which has been suggested to last up to 3–14 days (Backer et al., 2020; Liu
et al., 2020). Complications in the immune response or infection occurring in those who already
have underlying health conditions, may result in more serious symptoms such as pneumonia or
acute respiratory distress syndrome (ARDS) which can often be fatal. This incidence of fatality
paired with the ease of viral transfer which often occurs through droplet and aerosol transmission
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is what makes this particular strain of coronavirus so deadly
(Rothan and Byrareddy, 2020).
There is current debate into the significance of the political
action of many countries which could have prevented the spread
from having such a global impact and whether more could have
been done to better prepare healthcare services to deal with the
virus. Having been better equipped, hospitals may have likely
been able to decrease the overall rates of death from the virus.
Regardless of where the responsibility for this pandemic lies, it
is clear that we currently rely on international collaboration and
extensive scientific prowess to deal with the issue and recover
from it in a way which will best reduce the impact it can cause
in the future.
One such avenue of investigation is the use of biosurfactants
which have proven themselves to be significant in a variety of
processes, all of which being crucial in managing the pandemic
by dealing with both the virus itself and the symptoms in which it
can cause. The structure of the coronavirus, similarly to others
of this type, consists of a lipid membrane which encloses its
vital proteins and positive sense RNA (Vellingiri et al., 2020).
This is an incredibly simple structure but can cause tremendous
harm when its membrane fuses with that of an animal cell,
allowing its RNA to be synthesized by the host. This will
result in the replication of the virus with the use of the host’s
cellular mechanisms spreading to other cells in the body, causing
exponential damage in the process. The lipid membrane, along
with embedded spike proteins is crucial in the virus’s ability to
both maintain its integrity and also pass our cells’ phospholipid
bilayer which allows it to initiate its mechanism of infection (Das,
2020). The amphiphilic nature of biosurfactants allows them to
interact with the hydrophobic domain of the viral membrane
with a significant enough affinity to disrupt it, resulting in a
breakdown of its structure and therefore disabling it.
Biosurfactants are currently used across a large range of
industrial and medical processes and their innate versatility
open up their use for a large variety of coronavirus related
applications (Randhawa and Rahman, 2014). In dealing with this
pandemic, it is crucial that we target the virus at every stage
of its transmission and incubation. The use of biosurfactants
will therefore be considered in handwashes and cleaning agents
to prevent the spread of the virus; targeting and relieving the
symptoms after infection; acting as drug delivery systems and
additionally their use in other important areas with a key example
being the production reliable antiviral facemasks.
BIOSURFACTANT STRUCTURE AND
FUNCTION
Biosurfactants are defined as being amphiphilic moieties which
possess the ability to reduce surface tensions across the interface
of typically polar substances such as oil and water, therefore
exhibiting emulsification properties. Biosurfactants stand out
from synthetic surfactants mainly because of their biological
and therefore renewable origins, being predominantly made
by microbial species and some plants. Compared to their
synthetic counterparts biosurfactants have greater emulsification
activities, work across a broader range of temperature conditions
and most importantly, they have been proven to exhibit a
significantly low degree of cytotoxicity (Abdel-Mawgoud et al.,
2010). The amphiphilic nature of biosurfactants means that
their hydrophobic domain is able to interact with the lipid
membrane of the virus, while simultaneously interacting with
other hydrophilic substances such as water. This property is
what allows them to disrupt the virus structure and therefore
deactivate it (Sandeep and Rajasree, 2017).
Biosurfactants additionally have an interesting trait in which
they are able to form micellar structures around their critical
micelle concentration (CMC), a value that differs greatly
between the different biosurfactant types. This structure will be
significant in directly targeting the virus, impacting its overall
emulsification activity, while also being crucial in our application
of biosurfactants in drug delivery. The micelles have the potential
to work as liposomes which could directly deliver a drug to
the site of infection while also protecting it from the harsh
conditions in the body which would otherwise impact its function
(Nakanishi et al., 2009).
The versatility in the use of biosurfactants alongside their
already large presence in both the pharmacological and food
industries prove them to be a significant route in finding novel
solutions to the COVID-19 pandemic, therefore justifying their
extensive researchmoving forward (Campos et al., 2013; Fracchia
et al., 2018; Nitschke and Silva, 2018; Ribeiro et al., 2020).
Mechanism of Action of Biosurfactant in
Humans
Due to biosurfactant unique chemical structures, understanding
the functional mechanisms of action as well as their toxicity to
human body is crucial for their exploitation in medical field.
Nowadays, biosurfactant find applications as antimicrobial, anti-
adhesive, in immunomodulation and as antitumor. Lipopeptides
and glycolipids are the most effective as antimicrobial and
represents an important source for the discovery of new
antibiotics. Biosurfactant have been shown in mammalian cells,
to participate in several intercellular molecular recognition steps
such as signal transduction, cell differentiation and cell immune
response acting as antitumor agents by interfering with cancer
progression processes (Gudiña et al., 2013; Fracchia et al., 2015;
Sajid et al., 2020).
The antimicrobial and anti-adhesive properties of
biosurfactant relays on membrane damage/disruption, causing
metabolite leakage by modification of membrane protein
morphology; by affecting energy generation and metabolites
transport as well as by altering the bacterial lipopolysaccharide
system (LPS), thus reducing cell adhesion and biofilm formation
(Van Hamme et al., 2006; Fracchia et al., 2015). Different
lipopeptides have reached a commercial antibiotic status, like
echinocandins, micafungin, anidulafungin, and daptomycin
(Fracchia et al., 2015). Moreover, some biosurfactant have shown
immunomodulation activities (Sajid et al., 2020). As examples
surfactin is an interesting molecule, believed to reduce the
activity of macrophage by down regulating the expression of
several cell surface molecule (i.e., CD54), thus being a potential
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candidate in the treatment of hypersensitivity related immune
disorders (Paine et al., 2002). Surfactin is also known to have
anti-inflammatory activities because of its inhibitory properties
on phospholipase A2, on the release of interleukin and nitric
oxide (Kim et al., 1998; Byeon et al., 2008; Backhaus et al.,
2017). In a similar way sophorolipid injection in animals showed
inhibition of pro-inflammatory cytokine and nitric oxide in the
treatment of sepsis (Fu et al., 2008). Biosurfactant have been also
proposed as new molecule for the treatment of autoimmune
diseases as well as potent immuno-modulator and anticancer
agent (Sajid et al., 2020).
Despite their versatility some biosurfactant are produced
by opportunistic bacteria and it is essential to consider their
in vivo toxicity and safety. Scarcity of clinical data on the
use and validation of such molecules in animal models and
human volunteers pose a major challenge. Nonetheless, some
biosurfactants have proven their efficacy in different sectors,
fulfilling drug regulatory bodies requirements as biocompatible
and non-toxic molecules.
Anti-viral Applications of Biosurfactants
Although reasons behind microbial biosurfactant production are
currently unresolved, a likely explanation has been proposed
through evolutionary analyses. This view recognizes competitive
advantages generated through biosurfactant production, aiding
in areas such as resource acquisition and defense, therefore
increasing survivability when compared to other organisms who
may be disadvantaged as a result (Cameotra et al., 2010; Kiran
et al., 2015). Biosurfactant production has often been found to
occur where species have experienced depleted resources, as well
as during times where they may benefit from their antimicrobial
nature. Previous studies have explored the defensive nature of
surfactants by expanding the application of bioactive peptides
to inactivate enveloped viruses. Cyclosporin A (CsA) is a bio-
peptide produced from the fungus Tolypocladium inflatum,
already known to inhibit the propagation of the influenza virus
by interfering with the viral cycle (Garoff et al., 1998; Khan,
2017). CsA does not affect adsorption or RNA replication but
instead inhibits steps after protein synthesis, such as assembly
or budding (Garoff et al., 1998). This is extremely important as
budding enables viruses to exit host cells and attach to derived
membranes enriched in viral proteins encouraging spread and
infection (Hamamoto et al., 2013). By targeting later events of the
virus life cycle the problem of resistance to available drugs will be
overcome as well as limiting spread. Lipopeptide used as adjuvant
or linked to low mass antigenic molecules have also been used to
stimulate the immune system to produce antibodies. Synthetic
lipopeptide vaccines have been shown to be able to induce
virus specific cytotoxic T-lymphocytes against the influenza
nucleoprotein epitope (Deres et al., 1989). Similar results have
been observed against foot-and-mouth disease in vivo B- and Th-
cell response toHIV-1 (Wiesmüller et al., 1989; Loleit et al., 1996).
This might have a very interesting application in novel vaccines
discovery and production. Sophorolipids (SL), a group of
microbial glycolipids produced by yeasts have shown properties
as immunomodulators, anti-inflammatory and improved sepsis
survival in experimental animal models (Borsanyiova et al.,
2016). By acetylation of the sophorose head groups, SL have been
active against herpes virus and HIV virus. Such modification is
considered to improve hydrophilicity of SL thus promoting its
antiviral and cytokine-stimulating property (Shah et al., 2005;
Gross and Shah, 2007).
These are potential issues that may arise with SARS-CoV-2.
This necessitates for the screening of potential agents with novel
modes of action to eliminate harmful life-threatening effects.
Biosurfactants Applied as Cleaning
Products
Timely antiviral administration is key throughout global
pandemics and the prompt treatment of ill individuals is key to
managing future cases. Extreme measures such as closing public
areas and social distancing may reduce the infection rate of a
disease. However, only antiviral drugs or vaccines are effective
in curing and preventing infection when directly exposed to
SARS-CoV-2. When facing a new and previously uncategorized
virus, vaccine production is likely to be a slow process—unless
the viral strain closely resembles a previously identified virus
in which we have pre-established treatments. Therefore, during
such unprecedented times, before a cure is available it is vital to
encourage safe and efficient cleaning procedures that effectively
eliminate dormant forms of the virus that may lay on surfaces in
public areas, clothes or homes.
Anionic surfactant types are commonly used in cleaning
products and detergents. When applied to a surface the
fatty acid chains of the surfactant bind to the hydrophobic
components of microbes, while the surfactants hydrophilic
domain will simultaneously bind to water with a significant
affinity, resulting in the solubilization of that microbe. This
emulsification reaction therefore enables the surface to be
cleaned whilst depositing an effective surfactant layer. Once
attached the anionic detergent particles electric charge removes
harmful substances from the surface and solubilize them into
smaller droplets which results in an emulsification of dirt and
detergent. As the surfactant molecules are continuously attached
to the dirt/harmful substance the process of repulsion continues
effectively preventing the same particle from being reintroduced
to the surface. A visual is shown in Figure 1.
Surfactants are the single most important ingredients in
laundry and household cleaning products and typically account
for 15–40% of total detergent composition (Yangxin et al., 2008).
Through increased research, various combinations of surfactant
types as well as alterations to surfactant volume within existing
and new products have proven surfactants to be effective over
traditional products such as bleach. There is no doubt that
bleach has proven itself to be an incredible antimicrobial agent
with its active ingredient sodium hypochlorite being effective
in destroying bacteria, fungi and viruses. However, bleach can
irritate skin, airways and mucus membranes, which suggests
prolonged exposure to be harmful. Bleach also decomposes under
heat and light and reacts easily with other chemicals decreasing
its effectiveness. Improper use of bleach such as deviations from
recommended dilutions may also affect performance and its
overall use is likely to carry with it its own environmental
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FIGURE 1 | (A) Structure of a biosurfactant molecules. (B) Interaction of biosurfactants solution with dirt. (C) Expected effect of biosurfactants on coronavirus.
implications which increase in significance when we consider
the large-scale washing of public areas to prevent viral spread.
All the issues stated above highlight how using bleach alone
for disinfection in public areas or areas of high risk such as
hospitals/surgeries can involve injury to health-care workers
and increase immunosuppression which may lead to increased
susceptibility to SARS-CoV-2 especially in areas where exposure
to the virus is more likely [World Health Organization (WHO),
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2014]. Therefore, using products that contain biosurfactants in
conjunction with or as an alternative to heavily chemical cleaners
may be more effective in efficient disinfection.
Biosurfactants have great advantages as eco-friendly and less-
toxic alternative to synthetic surfactant and to date, glycolipids
(sophorolipids, rhamnolipids, and mannosylerythritol lipids) are
the most commercialized in cleaning applications by different
companies world-wide. Companies like Saraya, Ecover, and
Henkel apply SL in their laundry, dishwashing and cleaning
products whereas BASF, Evonik, TeeGene and Unilever are
commercializing rhamnolipids and lipopeptide biosurfactants
based products (Klosowska-Chomiczewska et al., 2011; Fracchia
et al., 2014; Randhawa and Rahman, 2014; Singh et al., 2019).
Handwash Applications of Biosurfactants
Since the start of the pandemic in December 2019, demand
for various products -especially gloves, soaps, disinfectants and
hand sanitizers has increased dramatically. A huge emphasis has
arisen on the necessity of cleanliness, specifically the efficient
cleaning of hands after coming into contact with potentially
contaminated surfaces both indoors and outdoors. Due to this,
governments globally have had to update and define technical
and regulatory standards for such products to ensure safe practice
and manufacture whilst dealing with the pandemic. Information
regarding proper hand washing techniques as well as products
content has been published. Specifically, the UKGovernment has
released technical specifications for the production of hand wash
and associated legislation of personal protective equipment (PPE)
as well as prerequisites before items are sold. Stricter regulations
ensure consistency and guaranteed effectiveness of hand washing
products which are vital during times of a pandemic (Cabinet
Office GOV.UK, 2020)
The effectiveness of hand sanitizers compared to washing
hands with soap and water has been of constant debate as of
recently. The C.D.C (Center for Disease Control and Prevention)
has stated that using soap when washing hands is more effective
than hand sanitizer or water alone [Centers for Disease Control
and Prevention (CDC), 2019]. This is because surfactants present
in soaps lift and remove microbes, harmful substances and dirt
from skin. Furthermore, the lather produced from soap as well as
effective scrubbing work well to remove contaminants.
The use of alcohol-based hand sanitizer that contain at least
60% alcohol is still recommended if washing hands with soap is
not available. Hand sanitizers do not get rid of all types of germs
and may not be as effective where hands are excessively greasy
or dirty [Centers for Disease Control and Prevention (CDC),
2019]. Alcohol is extremely effective, but efficacy differs among
different types. For example, ethyl alcohol (70%) is a powerful
germicide and is considered generally superior to isopropyl
alcohol. It is also important to consider the prolonged and
repeated use of alcohol-based products such as a disinfectant
which can cause discoloration and damage to the skin [World
Health Organization (WHO), 2014]. Whereas, TeeGene has
reported about lipopeptide and rhamnolipid biosurfactant based
cosmetics (Randhawa and Rahman, 2014; Focus on Surfactants,
2015) and Evonik has reported their sophorolipid biosurfactant
for skin conditioning, refatting and moisturizers properties
to be used in shampoo, shower gel and household cleaners
(Focus on Surfactants, 2016) and it also has a potential use in
handwash applications.
Biosurfactants Application in Acute
Respiratory Distress Syndrome (ARDS)
Acute respiratory distress syndrome (ARDS) is a progressive
medical syndrome, characterized by a build-up of fluid in the
patient’s alveoli which result in inefficient oxygen transfer across
these alveolar membranes into the blood (Matthay et al., 2019).
ARDS is often a consequence of an already serious medical
concern, in this case Covid-19, with the resulting lack of oxygen
to organs contributing to the high fatality rates seen in those who
begin to develop symptoms (Ware and Matthay, 2000).
One leading cause for this alveolar fluid build-up, in
response to infection by SARS-CoV-2, is surfactant dysfunction
which has negative consequences on the emulsification and
thereby clearance of liquid from this particular region. Current
treatments for this rely on ventilators to supplement the
body with the oxygen which otherwise would not be able to
successfully transfer into the blood, relieving the immediate
symptoms which would otherwise lead to issues such as hypoxia
(Luks et al., 2020). Socioeconomic factors have played a large role
in the effectiveness of such a treatment, with providing enough
ventilators and facilities for each patient affected proving to be
difficult and, in some cases, impossible considering the cost, space
and training required to use them.
With this in mind, biosurfactants present themselves to be a
promising area of study in identifying novel treatments for ARDS
which could overcome the socioeconomic barriers that have so
far limited the effectiveness of ventilators. It is for this reason
that future study for their use as a direct treatment for ARDS,
through solubilizing the alveolar substrate, is likely to generate
positive results and is therefore crucial in combating Covid-19 in
the future.
Biosurfactants and Drug Delivery
Mechanisms
When considering possible treatment opportunities for the
COVID-19 pandemic, it is crucial to decide upon a mode of drug
delivery which doesn’t compromise the molecular nature of the
product while also being able to deliver it successfully to the area
of interest. With the SARS-CoV-2 predominantly impacting the
respiratory system and upper gastrointestinal tract, a likely mode
of delivery would be via aerosol or lozenge. Themicellar nature of
biosurfactants result in them being the ideal candidates for either
system of drug delivery, allowing them to form a stable liposome
which will encase the drug, protecting it from damage which may
otherwise cause dysfunction (Sosnowski and Gradon, 2009). The
physicochemical characteristics of biosurfactants allow them to
maintain their integrity while used in an aerosol, this would be
the likely mode of drug delivery considering the main area of
virulence to be within the lungs.
The solubility of biosurfactants will work to their advantage
throughout this process as they will evidently increase the
bioavailability of the drug, once it has been administered. This
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self-solubilising nature of biosurfactants therefore advances the
drugs dose proportionality, resulting in more consistent impacts
across patients (Omkar et al., 2020). The ability for biosurfactants
to mediate drug delivery is apparent, however the benefits of
their use in this way are 2-fold. In addition to providing safe
passage for the drug to the target, the biosurfactants will also
exhibit natural antiviral properties at the site of infection, in
addition to also relieving surfactant dysfunction in the alveoli,
another consequence of SARS-CoV-2 infection. In this way, they
will be able to inhibit a number of viruses present around that
given area while also directly relieving symptoms, a significant
factor reducing its virulence and transmission between hosts.
This characteristic has furthermore been expanded upon as
researchers ponder the ability for biosurfactants to themselves
behave as a treatment in this way. One such example includes
the addition of clinically approved biosurfactants in gummies or
lozenges, as they are consumed the biosurfactants will directly
reach parts of the mouth and esophagus which may be impacted
and therefore provide symptomatic relief (Vellingiri et al., 2020).
In addition to this, the biosurfactant will likely form a vapor in
the mouth which can be inhaled through the process of ingestion,
allowing it to reach areas of the respiratory tract to potentially
provide relief in that area as well.
CONCLUSION
The COVID-19 pandemic is one which has had a detrimental
impact on public health, seriously hindering the normal
functionality of our society and therefore resulting in massive
hardship across both our economy and public well-being. It is for
this reason that scientists have been at a bid to find novel ways in
which this pandemic can be combatted, across all of its planes of
influence throughout our society.
Biosurfactants have not only proven themselves to be the ideal
candidates to behave as this novel solution but have done so
in a way which targets many of the avenues that are crucial in
resolving a pandemic of this scale. Their potential in behaving
as safe and effective cleaning solutions have been discussed
and they have been recognized as being a valid alternative
to current procedure. In addition to this, biosurfactants have
been found to act as significant drug delivery systems, housing
multiple benefits to their use, most importantly showing a great
potential in being able to successfully deliver drugs, maintaining
dose proportionality in the process. Finally, the potential for
biosurfactants to exhibit medicinal qualities in the treatment of
SARS-CoV-2 infection, particularly in the relief of symptoms
associated with ARDS, have shown exceptional promise. The
lack of knowledge shrouding this phenomenon therefore
justify extensive future research. A prominent barrier remains
in the large production costs associated with biosurfactant
bioprocessing, a significant factor which must not be overlooked
and should remain a focal point for future study. Reducing
the cost of bioprocessing, alongside the continued research of
biosurfactant applications in this area are key to success within
this field.
The incredible versatility found across the structure and
functions of biosurfactants mean that their reach in effectiveness
is by no means limited to the applications which have been so
far highlighted. As research progresses in this area, the feasibility
of both their use and their socioeconomic development increase.
The results of this pandemic have been so far detrimental
however, it is crucial that we push forward and adapt such
ideas in finding the very solutions that we need to combat the
consequences of this virus and pathogens in the future. In this
way, biosurfactants bring promise to a scenario that is often
shrouded in despair, with research and scientific prowess we
will not only overcome the issues of this pandemic, but we will
additionally better equip ourselves for the future.
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